New Stocks Make Most Attractive/Dangerous Lists For March
Our Most Attractive and Most Dangerous stocks for March were made available to the public at midnight on Wednesday.
Trending on the Topix Network
Laboratory Network .com
Ambry Genetics Prevails In Preliminary Injunction Motion Filed By Myriad Genetics
Ambry Genetics , the worldwide leader in hereditary cancer testing, announced today that it has successfully defended itself against the preliminary injunction motion filed on July 9, 2013 by Myriad Genetics and other plaintiffs in University of Utah Research Foundation et al. v.
Wed Mar 12, 2014
Utah Judge Denies Myriad's Preliminary Injunction Motion
In a 106-page opinion, U.S. District Court Judge Robert J. Shelby on Monday denied Myriad Genetics motion for preliminary injunction in Myriad Genetics v.
Tue Mar 11, 2014
Investor's Business Daily
Market Rallies; Green Mountain Changes Its Name
The Nasdaq rose 0.4%, the S&P 500 was up 0.2% and the Dow Jones gained 0.1%. Volume was up on the Nasdaq, but down on the NYSE.
Mid-Day Market Update: Men's Wearhouse To Acquire Jos. A. Bank For $65/Share; Myriad Shares Slip
Midway through trading Tuesday, the Dow traded down 0.30 percent to 16,369.34while the NASDAQ tumbled 0.17 percent to 4,327.24.
UPDATE 1-US court denies Myriad motion to block rival genetic tests
Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company.
Wall Street set to open flat
US stocks were set for a flat open on Tuesday after a slight decline in the prior session left the S&P 500 within striking distance of its recent record high and amid investor caution as tensions in Ukraine continued.
Investor's Business Daily
Stocks Futures Effectively Flat; Boyd Gaming Up, Myriad Dives
Dow futures backed out of thin, early gains and were a mild 2.7 points below fair market value.
Press Digest- New York Times business news - March 11
The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
Mon Mar 10, 2014
USPTO Guidance for Examiners Takes Expansive View of Myriad and Prometheus Decisions
On March 4, 2014, the U.S. Patent and Trademark Office issued a memorandum to the Patent Examining Corps with guidance for determining the patent eligibility of claims relating to products of nature and laws of nature in view of the U.S. Supreme Court decisions in Assoc.
Sat Mar 08, 2014
USPTO Issues Guidance for Examining Process Patents
On March 4th, 2014, the U.S. Patent and Trademark Office issued " 2014 Procedures For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products" Guidance , advising examiners and the public of the factors for determining whether an invention satisfies the U.S.
Fri Mar 07, 2014
Mayo, Myriad, and Multi-factor balancing tests
On the same day that the Supreme Court's opinion was handed down in Assoc. for Mol.
The Motley Fool
The Nasdaq's 5 Most Hated Stocks
I actually had to do some digging to come up with the date of April 7, 2000 as the last time the technology-heavy Nasdaq Composite closed at a higher point than it did earlier this week.
Thu Mar 06, 2014
USPTO to Apply Myriad Beyond Isolated DNA
Today, the United States Patent and Trademark Office issued a Guidance , advising examiners and the public of the factors for determining whether an invention satisfies the U.S. Supreme Court's interpretation of 35 U.S.C. A 101, as applied to patent-eligibility.
Mon Mar 03, 2014
Myriad publishes clinical utility study for Prolaris
Myriad Genetics, Inc. today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion , demonstrating that 65 percent of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test.
Wed Feb 26, 2014
Myriad Genetics Director Walter Phd Gilbert Unloads 30,000 Shares
Myriad Genetics Director Walter Phd Gilbert unloaded 30,000 shares of the stock in a transaction dated Wednesday, February 26th.
Fri Feb 21, 2014
Recently released market study: Crescendo Bioscience, Inc. - Medical...
It develops quantitative, objective, and biology based tests to provide rheumatologists with deeper clinical insights to enable more effective management of patients with autoimmune and inflammatory diseases.
Thu Feb 20, 2014
Medical News Today
Data shows Prolaris test predicts metastases in prostate cancer from biopsies
Myriad Genetics, Inc. has announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence or metastatic disease following radical prostate surgery.
Wed Feb 19, 2014
Five Star Equities Issues New Research Reports on CCIH, CMLS, LTBR...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.